Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,760
datasets available to search
ShareScore release 0.9.0
Dataset results
1,760 results for “phase 2”
Data from: Cephalic phase of insulin secretion in response to a meal is unrelated to family history of Type 2 diabetes
The pre-absorptive cephalic phase of insulin secretion is elicited during the first ten min of a meal and before glucose levels rise. Its importance for insulin release during the post-absorptive phase has been well documented in animals but its presence or importance in man has become increasingly controversial. We here examined the presence of an early cephalic phase of insulin release in 31 well matched individuals without (n=15) or with (n=16) a known family history of type 2 diabetes (first-degree relatives; FDR). We also examined the potential differences in individuals with or without impaired fasting (IFG) and impaired glucose tolerance (IGT). We here demonstrate that a cephalic phase of insulin secretion was present in all individuals examined and without any differences between control persons and FDR or IFG/IGT. However, the overall importance of the cephalic phase is conjectural since it was unrelated to the subsequent post-absorptive insulin release or glucose tolerance. One of the best predictors of the incremental cephalic phase of insulin release was fasting insulin level and, thus, a relation to degree of insulin sensitivity is likely. In conclusion, an early pre-absorptive and cephalic phase of insulin release is robustly present in man. However, we could not document any relation to family history of Type 2 diabetes nor to the post-absorptive phase and, thus, confirm its importance for subsequent degree of insulin release or glucose tolerance.
Fig 2 from: Tanaka S (2024) Geographic variation in body size of the migratory locust Locusta migratoria (Orthoptera, Acrididae): Masaki's cline and phase polyphenism. Journal of Orthoptera Research 33(1): 27-40. https://doi.org/10.3897/jor.33.107242
Fig 2 Diagram showing compositions of Locusta migratoria populations with 1, 2 and 3 or more generations per year based on various sources (H. Tanaka 1982, Hakomori and Tanaka 1992, Tanaka 1994, Shimizu et al. 2012, Tanaka 2022).
Global gene expression analysis of Streptococcus agalactiae at exponential growth phase_Table 2
<p>Top-100 most expressed genes by functional category.</p>
Repurposing Domperidone in Secondary Progressive MS - A Simon 2-Stage Phase 2 Futility Trial - Table e1: Results of the binary logistic regression model
<p><b>Objective:</b> To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon two-stage design.</p> <p><b>Methods:</b> We enrolled patients in an open-label, Simon two-stage, single-center, phase 2, single-arm futility trial at the Calgary MS Clinic if they met the following criteria: age 18 to 60 years, SPMS, screening EDSS score of 4.0 to 6.5 and screening T25FW of 9 seconds or more. Patients received domperidone 10mg QID for one year. The primary outcome was worsening of disability, defined as worsening of the T25FW performance by 20% or more at 12 months compared to at baseline. This trial is registered with ClinicalTrials.gov, number NCT02308137.</p> <p><b>Results:</b> Between February 13<sup>th</sup>, 2015 and January 3<sup>rd</sup>, 2020, 110 patients were screened, 81 received treatment, 64 completed follow-up, of whom 62 were analysed. The study did not meet its primary endpoint: 22 of 62 (35%) patients experienced significant worsening of disability, which is close to the expected proportion of 40%, and above the pre-defined futility threshold. Patients with higher prolactin levels during the study had a significantly lower risk of disability progression, which may warrant further investigation. Domperidone treatment was reasonably well tolerated, but adverse events occurred in 84% and serious adverse events in 15% of patients.</p> <p><b>Conclusions:</b> Domperidone treatment could not reject futility in reducing disability progression in SPMS. The Simon two-stage trial model may be a useful model for phase 2 studies in progressive MS.</p> <p><b>Classification of Evidence:</b> This study provides Class III evidence that in individuals with secondary progressive multiple sclerosis participating in a futility trial, domperidone treatment could not reject futility in reducing disability progression at 12 months.</p>
Survey questions in PDF-What industry wants from academia in software testing research (phase 2)
<p>Survey questions in PDF-What industry wants from academia in software testing research</p>
Data_Processing_Shintergy_Phase 2_ [6 to 10 May 24]_V.1_alcrlp
Open the record for dataset details and reuse information.
Figure 2 in Discrete dimorphism among castes of the bald-faced hornet Dolichovespula maculata (Hymenoptera: Vespidae) in different phases of the colony cycle
Figure 2. Scatterplot from the colonies in phase one, five colonies pooled.
Fig. 2 in Centipede diversity in patches of different development phases in an unevenly-aged beech forest stand in Slovenia
Fig. 2. Average density estimates of some centipede species from different development phases in an unevenlyaged beech stand at Is˘ka (Slovenia), based on soil samples in 2000.
Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
ClinicalTrials.gov study NCT01584505. IPD Sharing: YES. Countries: 6. Publications: 0.
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
ClinicalTrials.gov study NCT02688647. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
ClinicalTrials.gov study NCT01864538. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Biomarker Changes and Anxiolytic Effects-Phase 2
ClinicalTrials.gov study NCT04565145. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
ClinicalTrials.gov study NCT00482053. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase 2 Study for the Treatment of Superficial Lipomas
ClinicalTrials.gov study NCT00608842. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
ClinicalTrials.gov study NCT01976936. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P0
ClinicalTrials.gov study NCT00598208. IPD Sharing: Not stated. Countries: 0. Publications: 2.
A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris
ClinicalTrials.gov study NCT00525499. IPD Sharing: Not stated. Countries: 1. Publications: 0.
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma
ClinicalTrials.gov study NCT01018550. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
ClinicalTrials.gov study NCT00899847. IPD Sharing: NO. Countries: 1. Publications: 0.
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee
ClinicalTrials.gov study NCT00689273. IPD Sharing: YES. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.